Hims & Hers Health (NYSE:HIMS) Trading Down 2.9% - Time to Sell?
Hims & Hers Health (NYSE:HIMS) saw its stock price decline by 2.9% to $49.92, with trading volume increasing by 33%. Analysts have mixed ratings, with Citigroup maintaining a "sell" rating and a target price of $30, while Canaccord Genuity raised their target to $68 with a "buy" rating. The company reported a quarterly EPS of $0.20, exceeding estimates, and a revenue increase of 110.7% year-over-year. Insider trading activity included significant sales by executives, and hedge funds have been actively buying and selling shares.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price traded down 2.9% on Friday . The company traded as low as $48.87 and last traded at $49.92. 24,034,551 shares changed hands during trading, an increase of 33% from the average session volume of 18,134,518 shares. The stock had previously closed at $51.40.
Get Hims & Hers Health alerts:
Analyst Ratings Changes
- Hims & Hers Stock Rises on Fundamentals and Squeeze Potential
A number of brokerages have issued reports on HIMS. Citigroup reaffirmed a "sell" rating and issued a $30.00 target price (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday. Truist Financial lowered their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Bank of America boosted their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group raised their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $37.67.
Read Our Latest Analysis on Hims & Hers Health
Hims & Hers Health Price Performance
- Hims & Hers Stock Soars on Novo Nordisk Collaboration
The stock's fifty day moving average is $32.74 and its two-hundred day moving average is $32.16. The stock has a market capitalization of $11.31 billion, a P/E ratio of 115.73 and a beta of 1.84.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same period in the previous year, the company earned $0.05 earnings per share. The company's quarterly revenue was up 110.7% compared to the same quarter last year. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.
Insider Buying and Selling
- Hims’ Weight Loss Expansion: Real Growth or Just Hype?
In other news, insider Michael Chi sold 7,259 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $43.28, for a total transaction of $314,169.52. Following the completion of the transaction, the insider now directly owns 193,601 shares of the company's stock, valued at $8,379,051.28. This trade represents a 3.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 650,500 shares of company stock worth $25,790,311 in the last quarter. 17.71% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Hims & Hers Health
Hedge funds have recently bought and sold shares of the business. Means Investment CO. Inc. grew its stake in Hims & Hers Health by 23.5% during the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock worth $1,210,000 after buying an additional 9,508 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $18,048,000. State of Alaska Department of Revenue bought a new stake in Hims & Hers Health in the fourth quarter worth approximately $2,628,000. Pacer Advisors Inc. acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $374,000. Finally, Genesee Capital Advisors LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at $889,000. 63.52% of the stock is owned by institutional investors.
About Hims & Hers Health
(Get Free Report)Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading
- Five stocks we like better than Hims & Hers Health
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Google Is Betting Big on Nuclear Reactors—Should You?
- What is the MACD Indicator and How to Use it in Your Trading
- Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Hims & Hers Health Right Now?
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
